N/A N=140 Reducing Risk of Recurrence
Stroke · TIA · Hypertension
Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=600 Prevent Return of Stroke Study
Stroke Recurrence · Transient Ischemic Attack
Primary: Blood Pressure — 76; 65 percentage of participants
N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
Phase 4 N=2,716 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
Cerebral Infarction
Primary: Numbers of Patients With First Occurence of Stroke — 82; 119 participants — p=0.0357
Phase 2 N=15 Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Thrombosis
Primary: Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Phase 3 N=1,578 Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Ischemic Stroke
Primary: Incidence Rate of Stroke and TIA — 2.56; 2.65 events /100 person-years — p=0.8234
N/A N=258 Stroke Self-Management: Effect on Function and Stroke Specific Quality of Life
Stroke
Primary: Total Stroke Specific Quality of Life — 3.80; 3.82; 4.01; 3.94 units on a scale — p=0.0500
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
N/A N=492 Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin
Stroke, Acute
Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001
Phase 2 N=42 Safety Escalating Repeat IV, in Stroke Patients
Ischaemic Attack, Transient
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 11; 6; 8; 6 Participants
N/A N=129 Stroke Ready: A Stroke Preparedness Brief Intervention
Stroke
Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Phase 4 N=441 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Cryptogenic Symptomatic Transient Ischemic Attack · Cryptogenic Ischemic Stroke
Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006
Phase 2 N=47 Strength, Flexibility, And Balance Therapy After Stroke
Stroke
Primary: Balance - Measured With the Berg Balance Scale — 46.3; 43.8 units on a scale
N/A N=17 Comprehensive Cardiac Rehabilitation Feasibility After Stroke
Stroke, Ischemic
Primary: Attendance Rate — 8 Participants
N/A N=1,509 Stroke Ready - Optimizing Acute Stroke Care
Stroke, Acute · Stroke
Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients
Phase 3 N=88 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Transient Ischemic Attack · Stroke · Atrial Fibrillation
Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants
Phase 2 N=277 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086
N/A N=487 The SUCCEED Trial of Secondary Stroke Prevention
Stroke · Secondary Stroke Prevention
Primary: Systolic Blood Pressure — 133.1; 136.9 mm Hg — p=0.73
Phase 4 N=543 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
Cerebrovascular Accident
Primary: Telephone Modified Rankin Scale (Centralised, Blinded Assessment) — 58; 70; 75; 84 participants — p=0.683
N/A N=284 Stroke Swallowing Screening Tool Validation
Cerebrovascular Disorders · Deglutition Disorders
Primary: Sensitivity of Screening Items — 37.9; 3.5; 62.1; 10.3 percentage of agreement
Phase 2 N=162 Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
Stroke · Rhabdomyolysis · Jaundice
Primary: Total Number of Participants With an Increase in Liver Function Tests (LFTs) — 1; 2 Participants
N/A N=30 Stroke Education Intervention Trial - Pilot
Ischemic Stroke · Intracranial Hemorrhage · Transient Ischemic Attack
Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted
Phase 2 N=8 Poststroke Depression in Hemorrhagic Stroke
Stroke Hemorrhagic · Depression
Primary: Depression — 12.33; 6 units on a scale
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
N/A N=723 Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)
Thromboembolic Disease Recurrent · Deep Vein Thrombosis · Pulmonary Embolism
Primary: Validation of the Wells DVT Clinical Decision Rule — 67; 186; 148; 4 Participants
N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
Phase 3 N=5,390 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Stroke · Secondary Prevention
Primary: Adjudicated Recurrent Stroke — 4.09; 4.80 Annualised event rate (%/ year) — p=0.1028